 | | PRD_002479 | | Name: | Cyclic Peptide Inhibitor ZO1-GLN-SER-TPO-45W-MLL | | Formula: | C34 H48 F3 N6 O14 P | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002486 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[([1,1'-biphenyl]-4-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C49 H67 N5 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002487 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[(1H-indol-3-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C45 H64 N6 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_000323 | | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-[(1S,2R,3R)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-N~4~-[2-(d
imethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | | Formula: | C34 H53 N5 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000353 | | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-{(1S,2S)-1-(cyclohexylmethyl)-2-hydroxy-2-[(3R)-1,5,5-trimethyl-2-oxopyrrolidin-3-yl]ethyl}-N~4~-[2-(dimethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | | Formula: | C36 H54 N6 O5 S | | Definition date: | 2012-12-12 | | Last modified: | 2022-03-02 |
|
 | | PRD_000204 | | Name: | Vancomycin | | Formula: | C66 H75 Cl2 N9 O24 | | Description: | VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. | | Definition date: | 2012-12-12 | | Last modified: | 2022-01-06 |
|
 | | PRD_002455 | | Name: | D-PMI-omega | | Formula: | C82 H115 Cl N17 O20 | | Definition date: | 2021-11-17 | | Last modified: | 2021-11-17 |
|
 | | PRD_002454 | | Name: | Substrate-like cysteine protease inhibitor | | Formula: | C46 H70 Cl N10 O9 | | Definition date: | 2021-09-01 | | Last modified: | 2021-09-01 |
|
 | | PRD_002469 | | Name: | Inhibitor 18 | | Formula: | C30 H42 N4 O6 | | Definition date: | 2021-08-25 | | Last modified: | 2021-08-25 |
|
 | | PRD_002457 | | Name: | beta-D-glucopyranose-(1-4)-beta-D-glucopyranose-(1-3)-2-deoxy-2-fluoro-alpha-D-glucopyranose | | Formula: | C18 H31 F O15 | | Definition date: | 2021-05-19 | | Last modified: | 2021-05-19 |
|
 | | PRD_002383 | | Name: | des4.3.1 | | Formula: | C44 H74 N12 O11 S | | Definition date: | 2021-04-28 | | Last modified: | 2021-04-28 |
|
 | | PRD_002362 | | Name: | GsIN-1 peptide | | Formula: | C79 H106 N16 O21 S | | Definition date: | 2021-04-21 | | Last modified: | 2021-04-21 |
|
 | | PRD_002360 | | Name: | myristoyl thiourea inhibitor, No. 23 | | Formula: | C37 H67 N9 O5 S | | Definition date: | 2021-03-24 | | Last modified: | 2021-03-24 |
|
 | | PRD_002361 | | Name: | myristoyl thiourea inhibitor, No.13 | | Formula: | C39 H73 N12 O5 S | | Definition date: | 2021-03-24 | | Last modified: | 2021-03-24 |
|
 | | PRD_900134 | | Name: | Blood group B H type 2 antigen, beta anomer | | Formula: | C26 H45 N O20 | | Description: | oligosaccharide with branches | | Definition date: | 2021-02-17 | | Last modified: | 2021-02-17 |
|
 | | PRD_002449 | | Name: | (ACE)(1MH)D(B3L)F(1U8) | | Formula: | C44 H54 N6 O12 | | Definition date: | 2020-09-30 | | Last modified: | 2020-09-30 |
|
 | | PRD_002450 | | Name: | (ACE)(1MH)D(PF5)F(1U8) | | Formula: | C46 H45 F5 N6 O12 | | Definition date: | 2020-09-30 | | Last modified: | 2020-09-30 |
|
 | | PRD_002372 | | Name: | ACE-VAL-ARG-MET-QZA | | Formula: | C22 H43 Cl N7 O5 S | | Definition date: | 2020-09-16 | | Last modified: | 2020-09-16 |
|
 | | PRD_002373 | | Name: | ACE-VAL-ARG-MET-B2A | | Formula: | C20 H41 B N7 O6 S | | Definition date: | 2020-09-16 | | Last modified: | 2020-09-16 |
|
 | | PRD_002352 | | Formula: | C22 H31 N3 O7 | | Definition date: | 2020-09-02 | | Last modified: | 2020-09-02 |
|
 | | PRD_002315 | | Name: | 4HP-PRO-LYS-ARG-NH2, BM-30 | | Formula: | C25 H42 N8 O5 | | Definition date: | 2020-08-26 | | Last modified: | 2020-08-26 |
|
 | | PRD_002267 | | Name: | D-Arg4,Leu10-Teixobactin | | Formula: | C59 H101 N14 O14 | | Definition date: | 2020-08-19 | | Last modified: | 2020-08-19 |
|
 | | PRD_002187 | | Name: | tert-butyl [(4S,7S,10S)-7-(cyclohexylmethyl)-10-(hydroxymethyl)-5,8,13-trioxo-23-oxa-6,9,14,21,22-pentaazabicyclo[18.2.1]tricosa-1(22),20-dien-4-yl]carbamate | | Formula: | C30 H50 N6 O7 | | Definition date: | 2020-08-12 | | Last modified: | 2020-08-12 |
|
 | | PRD_002189 | | Name: | tert-butyl [(4S,7S,10S)-7-(cyclohexylmethyl)-10-(hydroxymethyl)-5,8,13-trioxo-22-oxa-6,9,14,20,21-pentaazabicyclo[17.2.1]docosa-1(21),19-dien-4-yl]carbamate | | Formula: | C29 H48 N6 O7 | | Definition date: | 2020-08-12 | | Last modified: | 2020-08-12 |
|
 | | PRD_002272 | | Name: | (3R)-3,6-diamino-N-({(2R,5R,8Z,11S,15S)-15-amino-11-[(4R)-2-amino-1,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-5-yl}methyl)hexanamide | | Formula: | C25 H44 N14 O7 | | Definition date: | 2020-08-12 | | Last modified: | 2020-08-12 |
|
